Regeneron Enters Most-Favored-Nation Drug Pricing Agreement with Administration

The administration announced an additional MFN drug pricing agreement with Regeneron, including Medicaid pricing commitments, TrumpRx access, tariff relief and approval for a newly approved gene therapy for rare genetic hearing loss.